FSIP1 and Alzheimer disease: To further explore the therapeutic potential of HSD10 inhibitors under disease-relevant conditions, their effects were tested in an Aβ42-enriched environment, which is known to exacerbate mitochondrial dysfunction and contribute to early neuronal damage in AD [56].